With an FDA advisory committee recommendation in hand, Lundbeck and Otsuka’s Rexulti is one step closer to locking down a new indication in Alzheimer’s disease related agitation. In a 9-1 vote on ...

Otsuka and Lundbeck’s CNS drug Rexulti has for the second time this year claimed the top spot as the leading TV drug ad spender. That’s according to the latest data out by real-time ad trackers ...

WASHINGTON (TND) — A medication has been approved to treat symptoms of dementia, theU.S. Food and Drug Administration (FDA) announced Thursday. The agency said Rexulti, an oral tablet, marks thefirst ...

For the first time, the Food and Drug Administration has approved a drug to treat agitation related to Alzheimer’s disease dementia. Patient advocates are hailing the news, but prescribing the drug, ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the Joint Meeting of the ...

The Food and Drug Administration has given Lupin tentative approval for brexpiprazole tablets, in dosage strengths of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. The medication is a generic of Otsuka ...

Rexulti (brexpiprazole) is a medication used to treat conditions like major depressive disorder (MDD), schizophrenia, and agitation associated with Alzheimer’s disease. Many Medicare Part D and ...

Agitation is one of the most common symptoms of Alzheimer’s disease, leading patients to become restless or even verbally and physically aggressive. The FDA has approved the first drug to treat these ...

Credit: Getty Images. Brexpiprazole is an atypical antipsychotic. The Food and Drug Administration (FDA) has approved Rexulti ® (brexpiprazole) for the treatment of agitation associated with dementia ...

In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast ...

Submission is based on extrapolation analysis and results examining the effects of Rexulti ® (brexpiprazole) 2 to 4 mg/day in treating symptoms of schizophrenia in adolescent patients (13-17 years old ...